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Abstract
Introduction About 70% of breast cancers express oestrogen
receptor  α (ESR1/ERα) and are oestrogen-dependent for
growth. In contrast with the highly proliferative nature of ERα-
positive tumour cells, ERα-positive cells in normal breast tissue
rarely proliferate. Because ERα expression is rapidly lost when
normal human mammary epithelial cells (HMECs) are grown in
vitro, breast cancer models derived from HMECs are ERα-
negative. Currently only tumour cell lines are available to model
ERα-positive disease. To create an ERα-positive breast cancer
model, we have forced normal HMECs derived from reduction
mammoplasty tissue to express ERα in combination with other
relevant breast cancer genes.
Methods Candidate genes were selected based on breast
cancer microarray data and cloned into lentiviral vectors. Primary
HMECs prepared from reduction mammoplasty tissue were
infected with lentiviral particles. Infected HMECs were
characterised by Western blotting, immunofluorescence
microscopy, microarray analysis, growth curves, karyotyping and
SNP chip analysis. The tumorigenicity of the modified HMECs
was tested after orthotopic injection into the inguinal mammary
glands of NOD/SCID mice. Cells were marked with a
fluorescent protein to allow visualisation in the fat pad. The
growth of the graft was analysed by fluorescence microscopy of
the mammary glands and pathological analysis of stained tissue
sections. Oestrogen dependence of tumour growth was
assessed by treatment with the oestrogen antagonist
fulvestrant.
Results Microarray analysis of ERα-positive tumours reveals
that they commonly overexpress the Polycomb-group gene
BMI1. Lentiviral transduction with ERα, BMI1, TERT and MYC
allows primary HMECs to be expanded in vitro in an oestrogen-
dependent manner. Orthotopic xenografting of these cells into
the mammary glands of NOD/SCID mice results in the formation
of ERα-positive tumours that metastasise to multiple organs.
The cells remain wild type for TP53, diploid and genetically
stable. In vivo tumour growth and in vitro proliferation of cells
explanted from tumours are dependent on oestrogen.
Conclusion We have created a genetically defined model of
ERα-positive human breast cancer based on normal HMECs
that has the potential to model human oestrogen-dependent
breast cancer in a mouse and enables the study of mechanisms
involved in tumorigenesis and metastasis.
Introduction
Classic epidemiological studies on the increase in cancer inci-
dence with age predicted that from three to six independent
events would be required to convert a normal cell into a tumour
cell [1]. Experimental studies have now proven that it is indeed
possible to transform a cell in culture by modifying the activity
of only a few critical genes. Cell lines quantitatively trans-
formed by expressing oncogenes or inactivating tumour
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suppressor genes have been produced from normal fibrob-
lasts, embryonic kidney cells and human mammary epithelial
cells (HMECs) [2,3]. The genes initially chosen for these stud-
ies were those encoding simian virus 40 large T and small t
antigen, activated Ras and telomerase. Subsequently it was
shown that viral oncogenes can be replaced by activated MYC
and genes targeting the retinoblastoma pathway [4]. This
combination will transform HMECs, but the resulting tumours
do not express oestrogen receptor α (ERα); this is an impor-
tant weakness of current models, because about 70% of
human breast tumours are ERα-positive.
ERα behaves quite differently in ERα-positive cell lines derived
from human breast cancer and in normal human mammary epi-
thelium in vivo. Oestradiol is a direct mitogen for ERα-positive
cancer cell lines, but in normal human breast tissue the ERα-
positive cells do not themselves divide in response to oestro-
gen [5]. Instead, they relay a proliferative signal to neighbour-
ing ERα-negative cells. The barrier to proliferation of ERα-
positive normal cells may explain why HMECs rapidly lose ERα
expression in culture and why the transformation studies per-
formed so far have produced ERα-negative tumour cell lines.
The target cell of oncogenic mutations in the breast is proba-
bly a stem cell or bipotent progenitor cell [6,7]. It is possible to
enrich for these cells by growing primary HMECs in the non-
adherent conditions previously developed for culture of neural
stem cells, leading to the formation of so-called floating mam-
mospheres [8]. The Polycomb-group gene BMI1  can sup-
press activation of the p53 and Rb pathways by silencing the
expression of p14ARF and p16CDKN2A [9] and it has been
shown to increase the rate of self-renewal of mammospheres
in response to Wnt, Hedgehog and Notch signals [10]. Since
Polycomb-group genes are overexpressed in breast cancer
[11,12], BMI1 is a relevant candidate to test in HMEC trans-
formation assays. BMI1 was originally identified as an onco-
gene that cooperates with MYC to induce lymphomas in mice
[13], and MYC is commonly amplified in breast cancer, so it is
reasonable to use MYC  in a transformation protocol that
includes BMI1. We show here that lentiviral transduction of
HMECs with ERα, BMI1, MYC and TERT leads to the forma-




Approval for culture of reduction mammoplasty tissue was
granted by the Lausanne University Hospital ethics committee,
and patients gave informed consent. The patients were healthy
women with no previous history of breast cancer. All samples
were confirmed by histopathological examination to be free of
malignancy. Primary HMECs and human mammary fibroblasts
(HMFs) were prepared by standard techniques [8,14].
HMECs were cultured in human mammosphere medium
(HMM): Hepes-buffered DMEM/F12 without phenol red
(Gibco, Basel, Switzerland) supplemented with 20 ng/ml EGF
(Invitrogen, Basel, Switzerland), 1 × B-27 (Gibco) and 1 nM
17-β-oestradiol (Sigma, Buchs, Switzerland). B27 is a serum-
free medium supplement containing antioxidants, vitamins,
growth factors and hormones including progesterone [15].
HMM was used for suspension and adherent culture of
HMECs; tissue culture plastic was not coated with collagen
for adherent culture. HMFs and MCF7 cells were grown in
DMEM containing 10% fetal calf serum. For the proliferation
assays, 20,000 cells were seeded per well in six-well plates in
duplicate and stained with crystal violet (Sigma) after 10 days
of culture in HMM containing 1 nM 17-β-oestradiol or 1 μM ful-
vestrant (ICI 182,780; Torcis Pharmaceuticals, Bristol, UK).
The area covered with cells was quantified with ImageJ soft-
ware (NIH, Bethesda, MD, USA). For the growth curves,
20,000 cells per well were seeded in 12-well plates in dupli-
cate in HMM containing 1 nM 17-β-oestradiol or 1 μM fulves-
trant. A separate plate was used for each time point and cells
were counted in a Neubauer chamber. For colony formation
and SNP assays from tumours, explanted cells were grown
briefly in puromycin to eliminate murine cells.
Lentiviral vectors
The pSD-69 plasmid contains the human phosphoglycerate
kinase (PGK) promoter, a Gateway attR cassette (Invitrogen),
the mouse PGK promoter and the puromycin acetyltrans-
ferase gene cloned into pRRLhPGK.GFP.SIN18 [16]. Prelim-
inary studies showed that the human PGK promoter is active
in mammospheres and differentiated HMECs. Gateway BMI1
and ESR1 clones were obtained from Flexgene (Boston, MA,
USA). The MYC (c-Myc) and TERT (hTERT) clones were pro-
vided by J Lingner and A Trumpp, respectively, and cloned into
pENTR1A (Invitrogen). The BMI1,  ESR1,  MYC  and  TERT
cDNAs were transferred to pSD-69 by LR recombination (Inv-
itrogen) to give pSD-84, 82, 94 and 83. The MYC clone was
wild-type in sequence. The β-glucuronidase gene (gusA) was
transferred from pENTR-GUS (Invitrogen) into pSD-69 by LR
recombination to give the control vector pSD-86. The cyan flu-
orescent protein gene (CFP) was cloned into pRRLh-
PGK.GFP.SIN18 from pECFP (Clontech, Saint-Germain-en-
Laye, France) by standard techniques to give pSD-25. Lentivi-
rus was produced by calcium phosphate transfection of 293T
cells [16]. To transduce HMECs with multiple genes, infec-
tions were performed simultaneously with different viruses:
cells were infected in suspension with the ERα and BMI1 vec-
tors 24 hours after harvest from the patient (that is, after diges-
tion with collagenase and dissociation of organoids to single
cells), grown in suspension for 6 days in ultra-low-attachment
dishes (Corning, New York, NY, USA), then dissociated,
plated and infected with the MYC, TERT and CFP vectors.
HMFs were infected with the CFP-expressing lentivirus in the
initial experiment to facilitate identification in mice but were not
transduced with TERT or transforming genes. The titre of each
lentiviral batch was determine d  o n  p r i m a r y  H M E C s .  A l lAvailable online http://breast-cancer-research.com/content/9/3/R38
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infections were performed at a multiplicity of infection of 50
viral particles per cell.
Antibodies
The following antibodies were used: antibodies against p14
(FL-132), p16 (M-156), MYC (9E10) (Santa Cruz Biotechnol-
ogies, Santa Cruz, USA); keratin 14 (RB-9020), keratin 18
(MS-142), progesterone receptor (PGR; Ab1), ERα (SP1),
high molecular weight keratins (AB-3; Neomarkers, Stehelin,
Basel, Switzerland); BMI1 (F6; Upstate, Lucerna-Chem AG,
Lucerne, Switzerland); β-tubulin (Sigma); GFP (A11122)
(Molecular Probes, Invitrogen); Ki67 (Novocastra, Newcastle,
UK) and hTERT (R484) [17]. For Western blotting, goat anti-
mouse or goat anti-rabbit antibodies coupled to horseradish
peroxidase (Jackson ImmunoResearch, Newmarket, UK) were
used, followed by chemiluminescent detection (Amersham,
Little Chalfont, Bucks., UK). For immunofluorescent staining of
tissue culture cells, samples were fixed with cold methanol.
For staining of tissue, samples were fixed for 2 hours at 4°C in
4% paraformaldehyde and embedded in paraffin. Antigens
were retrieved by boiling sections for 20 minutes in trisodium
citrate buffer pH 6. Goat anti-mouse or goat anti-rabbit anti-
bodies coupled to Alexa 488 or Alexa 568 (Jackson Immu-
noResearch) were used for detection and the slides were
mounted with 1,4-diazabicyclo [2.2.2]octane (DABCO;
Sigma).
Microarray analysis
RNA was extracted with an RNeasy kit (Qiagen, Hombrech-
tikon, Switzerland), amplified as described previously [18] and
hybridised to U133Plus 2.0 gene chips (Affymetrix, CA, USA).
CEL files were normalised with RMA [19]. The CEL files have
been deposited in the GEO database under accession
number GSE6548. DNA was extracted with a DNeasy kit
(Qiagen), and 250 ng per chip was processed and hybridised
to 50K HindIII SNP chips in accordance with the manufac-
turer's instructions (Affymetrix). The CEL files were analysed
with CNAG 2.0 [20].
Karyotyping
Cells were grown for 8 hours in HMM plus 100 ng/ml col-
cemid (Sigma). Metaphase spreads were prepared and
stained with Giemsa (Sigma) essentially as described [21].
Fifty-five metaphase spreads of HMEC strains established
from different donors were photographed and the chromo-
somes were counted.
p53 assay
RNA was extracted from HMECs before injection into mice
and from tumours in the fat pad with the use of an RNeasy kit
(Qiagen). p53 status was determined by yeast functional
assay with total RNA [22].
Orthotopic xenograft
Animal experiments were authorised by the Veterinary Office
of the Canton de Vaud, Switzerland. One million HMECs and
200,000 normal human mammary fibroblasts from separate
cultures were mixed with 12.5% Matrigel (BD Biosciences)
and injected into the fourth mammary gland of 8-week-old
female NOD/SCID mice (NOD.CB17-Prkdcscid/J; Jackson
Laboratory, Bar Harbor, ME, USA). Either the HMECs or the
HMFs expressed CFP but never both: only one cell type in a
single experiment was ever CFP-positive. The total time in tis-
sue culture ex vivo before the epithelial cells were injected into
the mammary fat pad was 28 days. Silicon pellets containing
1.5 mg of oestradiol [23] were inserted subcutaneously into
the neck region of the experimental animals at the time that the
cells were injected. For fulvestrant treatment, 5 mg of Faslodex
(AstraZeneca AG, Zug, Switzerland) was injected subcutane-
ously at weekly intervals. The oestrogen pellets were not
removed from fulvestrant-treated animals.
Results
BMI1 allows expansion of HMECs that express ERα
Microarray analysis of primary tumours [18] shows that the
Polycomb-group gene BMI1 is overexpressed in ERα-positive
tumours (Figure 1a; r = 0.62 for ESR1 versus BMI1, p = 4 ×
10-7; similar results were obtained in several other microarray
data sets) [24,25]. Because BMI1 suppresses growth arrest
mediated by the Rb pathway [9] and the early growth arrest of
HMECs has been linked to p16CDKN2A expression [26], BMI1
expression is a potential escape mechanism for growth-
arrested ERα-positive tumour cells. To test this, primary
HMECs were transduced with lentiviral vectors expressing
glucuronidase (GUS, which serves as a negative control), ERα
and BMI1. Cells transduced with GUS or ERα alone formed
small colonies. In contrast, transduction with ERα and BMI1
led to the formation of colonies that expanded to fill the dish in
less than 10 days (Figure 1b). ERα expression from the lenti-
viral vector was stable with passage and comparable to that
seen in the MCF7 breast cancer cell line (Figure 1c). In con-
trast, endogenous ERα expression was progressively lost with
passage: it was still present at passage 3, substantially
reduced at passage 4 (Figure 1c) and absent at passage 6
(Figure 1d). The exogenous ERα responded normally to regu-
lation at the protein level, showing the expected decrease in
level after treatment of the cells with the oestrogen antagonist
fulvestrant (ICI 182,780/Faslodex; Figure 1d). Immunostaining
confirmed the expression of both the ERα and BMI1 trans-
genes and showed that the encoded proteins localised to the
nucleus, as expected (Figure 1e). To create an ERα-positive
tumour model, cells expressing ERα and BMI1 were superin-
fected with lentiviruses expressing the c-myc  oncogene
(MYC) and the telomerase gene (TERT/hTERT). Western blot-
ting was used to test for expression of the transgenes. GUS-
transduced control HMECs did not express ERα, BMI1, MYC
or TERT (Figure 1f, lane 1), whereas ERα/BMI1/MYC/TERT-
transduced HMECs from three different donors showedBreast Cancer Research    Vol 9 No 3    Duss et al.
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robust expression of all four transgenes (Figure 1f, lanes 2 to
4).
To test whether the ERα and BMI1 transgenes were biologi-
cally active, a microarray experiment was performed on cells
after 10 days in culture. Oestradiol or fulvestrant was added to
cells for 12 hours to activate or block ERα signalling, respec-
tively. As expected, expression of the p16 gene (CDKN2A)
was suppressed by BMI1 (Figure 2a). This was confirmed at
the protein level by Western blotting for p14ARF  and
p16CDKN2A (Figure 1f; note that these cells were additionally
transduced with MYC  and  TERT). Several genes recently
shown by chromatin immunoprecipitation to be direct targets
of Polycomb complexes were also repressed, including BMI1,
CCND2 and NEFL (Figure 2b–d; the probe on the microarray
detects only the endogenous BMI1 transcript) [27]. Expres-
sion of many ERα target genes, including GREB1 (gene reg-
ulated in breast cancer 1), PGR (the progesterone receptor
gene) and PRLR (the prolactin receptor gene), was induced
by oestradiol and blocked by fulvestrant, but only in cells trans-
duced with ERα (Figure 2e–g). In contrast, several other clas-
sic ERα target genes, such as TFF1, showed little or no
response to oestrogen (Figure 2h; the full data set has been
deposited in the GEO database).
The medium used for both suspension and adherent culture
was HMM [8]. Because it is based on neurosphere medium
and the microarray showed the expression of some neural
genes, such as NEFL, we sought to confirm the epithelial
nature of the cells by staining for keratins. Control cells plated
after one round of mammosphere culture formed three types
of colony: pure keratin 18 (K18)-positive luminal colonies, pure
keratin 14 (K14)-positive myoepithelial colonies, and mixed
colonies containing both luminal and myoepithelial cells (Fig-
ure 1g, top panels). This is the same pattern as that reported
by Dontu and colleagues [8] after mammosphere culture; sim-
ilar observations have been made by other groups using differ-
ent HMEC culture conditions [28-30]. At later passages,
luminal cells were lost from the control cultures, resulting in the
formation of increasingly pure K14-positive myoepithelial cell
cultures (Figure 1g, middle panels). This is the expected result
when HMECs are put into culture (reviewed in [31]). In con-
trast with the single-positive staining pattern of the controls,
cells transduced with ERα and BMI1 were double-positive,
staining for both K14 and K18 (Figure 1g, bottom panels). We
conclude that the transduced cells are HMECs, the ERα and
BMI1 proteins are correctly expressed and biologically active,
and that BMI1 expression permits the outgrowth of ERα-posi-
tive colonies.
Figure 1
Expression of oestrogen receptor alpha (ERα) and BMI1 in human  mammary epithelial cells Expression of oestrogen receptor alpha (ERα) and BMI1 in human 
mammary epithelial cells. (a) Plot of microarray data [18] showing 
BMI1 expression in ERα-positive and ERα-negative breast tumours. 
BMI1 is significantly overexpressed in ERα-positive tumours (p < 
0.001). (b) Colony formation assay. Human mammary epithelial cells 
(HMECs) transduced with either glucuronidase (GUS; a negative con-
trol gene) alone, ERα alone or ERα and BMI1 were fixed after growth 
for 10 days in the presence of oestrogen and then stained with crystal 
violet. The surface area covered with cells in the fixed plates was used 
to estimate growth. (c) Western blot for ERα and β-tubulin in MCF7 
control cells or in passage 3 (P3, left) and passage 4 (P4, right) 
HMECs transduced with BMI1 alone or with ERα and BMI1 together. 
Endogenous ERα expression is progressively lost with passage. (d) 
Western blot for ERα, BMI1 and β-tubulin in passage 6 (P6) HMECs 
transduced with BMI1 alone or with ERα and BMI1 together. Before 
being harvested, cells were treated for 24 hours with 1 nM oestrogen 
(E) or 1 μM fulvestrant (F). Endogenous ERα expression is no longer 
detectable. Exogenous ERα is destabilised by fulvestrant. (e) Immun-
ofluorescent staining of HMECs infected with ERα and BMI1 viruses 
for ERα (lower left panel) and BMI1 (upper left panel). 4',6-Diamidino-
2-phenylindole (DAPI; right panels) was used to counterstain nuclei. 
ERα and BMI1 are both nuclear. (f) Western blot for TERT, ERα, BMI1, 
MYC, p14ARF, p16CDKN2A and β-tubulin in HMECs infected with control 
virus (GUS, lane 1) or ERα, BMI1, TERT and MYC lentiviruses. 
HMECs from three different patients are shown in lanes 2 to 4. The 
transgenes are expressed, and BMI1 suppresses p14ARF and 
p16CDKN2A expression. (g) Immunofluorescent staining of HMECs for 
keratin 14 (K14, green) and keratin 18 (K18, red). DAPI (blue) was 
used to counterstain nuclei. At passage 1, HMECs infected with con-
trol virus and plated at clonal density formed mixed colonies with cen-
tral K18-positive luminal cells and peripheral K14-positive myoepithelial 
cells (GUS P1). Passaging of these cultures led to progressive loss of 
luminal cells (GUS P4). HMECs infected with ERα and BMI1 viruses 
maintained K18 expression at passage 4, but individual cells were pos-
itive for both K14 and K18 (ERα BMI1 P4).Available online http://breast-cancer-research.com/content/9/3/R38
Page 5 of 15
(page number not for citation purposes)
Growth of ERα-transduced cells is dependent on 
oestrogen
Oestrogen is a direct mitogen for ERα-positive tumour cell
lines but not for normal mammary epithelial cells grown in vitro.
The proliferative cells in the normal epithelium have been
shown by immunostaining to be ERα-negative [5]. To test
whether our virally transduced HMECs can proliferate in the
presence of active oestrogenic signalling, oestradiol was
added to the medium and cultures were stained for ERα and
the proliferation marker Ki-67. Cells transduced with ERα
alone were rarely Ki-67 positive (less than 1%), whereas a
majority of cells transduced with both ERα and BMI1 were Ki-
67 positive (more than 70%; Figure 3a). BMI1 thus overrides
the negative control of proliferation by oestrogen in normal
ERα-positive cells. To test whether oestrogen is a mitogen for
the transduced cells, growth curves were performed in the
presence of oestradiol or fulvestrant. Transduction with BMI1
alone can produce a proliferative burst in low-passage cells,
but this disappears when endogenous ERα is lost (Figure 1d
and data not shown). Passage 6 cells transduced with single
genes failed to proliferate in any condition tested (Figure 3b).
Cells expressing exogenous ERα and BMI1 were able to pro-
liferate, and their growth was dependent on the presence of
oestradiol in the medium (Figure 3b, solid blue curves)
because it was blocked by fulvestrant (Figure 3b, dotted blue
curves). Cells cultured in medium containing the drug vehicle
(ethanol) without active drug had an intermediate growth rate
(Figure 3b, left panel, grey curves); because this growth was
blocked by fulvestrant it presumably reflects weak oestrogenic
activity in the B27 supplement in the serum-free medium. Cells
Figure 2
Gene expression profiles of HMECs transduced with GUS, ERα and BMI1 Gene expression profiles of HMECs transduced with GUS, ERα and BMI1. Cells transduced with GUS alone, ERα alone, BMI1 alone or ERα and 
BMI1 together were grown for 24 hours in the presence of oestrogen (E) or the oestrogen antagonist fulvestrant (F) to activate or block oestrogen 
signalling. Known BMI1 target genes (p16CDKN2A (a), CCND2 (c) and NEFL (d)) are repressed by BMI1. Endogenous BMI1 is also repressed in 
BMI1-transduced cells (b) (the probe on the array detects only the endogenous transcript; the Western blots in Figure 1 show that overall BMI1 
expression is increased in the BMI1-transduced cells despite the decrease in endogenous BMI1 expression). Many known oestrogen inducible 
genes are strongly induced by oestrogen receptor alpha (ERα) in the presence of oestrogen (e) GREB1 (gene regulated in breast cancer 1), (f) the 
prolactin receptor (PRLR) and (g) the progesterone receptor (PGR)), but some barely change ((h) TFF1). GUS, glucuronidase; HMEC, human 
mammary epithelial cell.Breast Cancer Research    Vol 9 No 3    Duss et al.
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transduced with MYC alone failed to proliferate; cells express-
ing MYC, ERα and BMI1 grew slightly faster than ERα/BMI1
cells but were still responsive to oestrogen in the medium (Fig-
ure 3b, right panel, green curves). We conclude that forced
expression of ERα and BMI1 bypasses normal controls on
mammary epithelial cell proliferation and produces cells that
are dependent on oestrogen for growth.
Creation of an ERα-positive tumour model
To test whether the cells transduced with ERα, BMI1, MYC
and  TERT  were transformed, they were injected into the
Figure 3
Growth of HMECs infected with the ERα virus is dependent on oestrogen Growth of HMECs infected with the ERα virus is dependent on oestrogen. (a) Immunofluorescent staining for oestrogen receptor alpha (ERα) and 
Ki-67 of human mammary epithelial cells (HMECs) grown in the presence of oestrogen. HMECs infected with the ERα and BMI1 viruses together 
are Ki-67-positive, whereas HMECs infected with the ERα virus alone are Ki-67-negative. (b) Growth curves of HMECs expressing the indicated 
transgenes in the presence of oestradiol (E) or fulvestrant (F). The left and right panels show HMEC strains from two different patients. ERα and 
BMI1 are necessary for proliferation; transduction with MYC leads to a further increase in proliferation (right panel). Proliferation is increased by oes-
trogen and blocked by fulvestrant. The grey curves, labelled EtOH in the left panel, show the behaviour of cells in the absence of exogenous oestro-
gen or fulvestrant.
Table 1
Tumour formation in NOD/SCID mice.
HMEC strain No treatment E2 E2 + fulvestrant
AJ 0/14 10/10 1/8
AK 0/14 12/12 3/6
U 0/4 11/12 0/8
Total 0/32 31/32 4/22
ERα/BMI1/TERT/MYC-transduced HMECs from three donors (AJ, AK and U) were injected into the inguinal mammary glands of NOD/SCID 
mice. Mice were divided into three groups: the control group (no treatment), which received no additional drugs (the cells were therefore exposed 
only to endogenous mouse oestrogen); the oestrogen-treated group, which received slow-release oestrogen pellets containing 1.5 mg of 
oestradiol (E2); and the fulvestrant-treated group, which received oestrogen pellets to allow engraftment followed after 32 days by weekly 
injections of fulvestrant to block oestrogen stimulation (E2 + fulvestrant). ER, oestrogen receptor; HMEC, human mammary epithelial cell.Available online http://breast-cancer-research.com/content/9/3/R38
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inguinal mammary glands of 8-week-old female NOD/SCID
mice. HMFs and Matrigel were injected with the epithelial cells
to promote engraftment [32]. In the first experiment, the HMFs
were tagged with a fluorescent marker protein (CFP). In the
absence of exogenous oestrogen, compact CFP-positive nod-
ules formed at the site of injection (Figure 4a,b). Histological
examination showed that the nodules contained a capsule of
fibrous tissue surrounding a core of necrotic epithelial cells
(Figure 4c). Necrosis of the epithelial component was seen in
20 grafts of HMECs from three different patients in this exper-
iment; this was confirmed in 12 grafts in a subsequent
experiment in which the HMECs rather than the HMFs were
tagged with CFP (Table 1, 'no treatment'). This shows that the
ERα/BMI1/MYC/TERT-transduced HMECs are unable to sur-
vive in the normal hormonal milieu of adult mice.
The physiological level of oestradiol is higher in women than in
mice, and it is frequently necessary to administer exogenous
oestradiol to study human oestrogen-dependent phenotypes
in mice [23]. The xenografts were therefore repeated in mice
given slow-release oestradiol pellets. In these experiments, the
HMECs were tagged with CFP. All except one of the 32
injected mammary glands developed tumours; the tumori-
genicity of the transgene-expressing cells was confirmed by
using HMECs from three different patients (Table 1, 'E2'). The
process of engraftment and tumour formation was followed by
killing mice at different time points (Figure 4d–f, day 5; then
Figure 4g–i, days 14, 21 and 35, respectively). Five days after
injection there was a large necrotic mass of tumour cells at the
site of injection, accompanied by a vigorous vascular response
(Figure 4e). On the surface of the mass, patches of brightly flu-
orescent CFP-positive epithelial cells were visible (Figure 4d).
Histological examination confirmed that the main mass was
Figure 4
Tumour formation in the mouse mammary gland Tumour formation in the mouse mammary gland. One million human mammary epithelial cells (HMECs) expressing oestrogen receptor alpha (ERα), 
BMI1, TERT and MYC were injected into the inguinal mammary fat pads of NOD/SCID mice; 2 × 105 HMFs were injected simultaneously with the 
HMECs to promote engraftment. (a-c) In the absence of exogenous oestrogen, fibrotic nodules containing HMFs but lacking epithelial cells were all 
that remained after 60 days. In this experiment only the HMFs were labelled with cyan fluorescent protein (CFP). (d-i) In the presence of exogenous 
oestrogen, HMECs readily formed invasive tumours. In this experiment only the HMECs were labelled with CFP. Time after injection: (d-f) 5 days, (g) 
14 days, (h) 21 days, (i) 35 days. (a,d,g-i), Fluorescence; (b,e), normal light; (c,f), haematoxylin/eosin staining. In (f) the open arrowhead indicates 
tumour, the filled arrowhead indicates mouse ducts, and the asterisk indicates necrotic cells at the site of injection. Note that HMFs were labelled 
with CFP in (a-c), whereas HMECs were labelled with CFP in (d-i): in each experiment only a single cell type was labelled with CFP.Breast Cancer Research    Vol 9 No 3    Duss et al.
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necrotic (Figure 4f, the asterisked region bounded by the dot-
ted line), presumably because it was insufficiently vascular-
ised, but the brightly staining patches on the surface
contained viable cells that were forming invasive tumour even
at this early time point (Figure 4f, open arrowheads; closed
arrowheads show mouse ducts). The absence of any lag sug-
gests that the cells are quantitatively transformed. Every sub-
sequent time point showed the presence of invasive tumour
cells with a similar histological pattern: dense islands of squa-
mous carcinoma adjacent to diffuse regions of invasive ductal
carcinoma. We conclude that HMECs transduced with ERα,
BMI1,  MYC  and  TERT  readily form oestrogen-dependent
tumours in mice.
ERα is active in the tumours
Immunostaining of the tumours for CFP confirmed that all of
the tumour cells were human in origin (Figure 5a,b). Matched
sections were tested to verify that the BMI1 and ERα trans-
genes were expressed (Figure 5c,d,j). ERα staining was
present in epithelial cells throughout the tumour (Figure 5d,f,j).
PGR, which is a direct target of ERα, was also expressed
throughout the tumour (Figure 5g,l). ERα staining was slightly
weaker in regions of strong PGR staining (compare Figure 5j
with Figure 5l). This is consistent with a previous report that
ERα is degraded at the promoter of target genes being
actively transcribed [33]. Staining for Ki-67 showed that the
ERα-positive cells were actively dividing (Figure 5d–f,j,k). Ki-
67 staining was stronger in invasive regions, as seen in the
merged image in Figure 5f, where there is more Ki-67 staining
in the invasive cells in the central and lower part of the figure,
and more ERα staining in the squamous cells in the upper right
part of the figure. Within squamous islands, Ki-67 staining was
generally stronger in regions with weaker ERα staining (Figure
5j,k). The squamous islands were strongly positive for K14
(Figure 5h) and a group of keratins expressed in squamous
epithelia (HMW keratin antibody against K1, K5, K10 and
K14, data not shown). Invasive regions expressed both K14
and K18 (Figure 5h,i). Interestingly, the cells forming a glandu-
lar structure in the centre of the squamous island in Figure 5a
(marked with an arrow) were positive for K18 despite being
buried within the K14-positive squamous tissue. To explore
further the keratin phenotype of the cells, tissue sections from
tumours harvested at multiple time points were examined (Fig-
ure 6). In addition to regions double-positive for K14 and K18,
the tumours contained single-positive regions expressing
exclusively K14 or K18. The tube-like structures seen in Figure
4g–i were reminiscent of mammary ducts, with an outer layer
of K14-positive cells and an inner layer of K18-positive cells
(Figure 6d,g,j; 14 days). After 35 days the tubes had formed
branches; most of the cells expressed K14 only but a signifi-
cant proportion co-stained for K14 and K18, and some areas
were strictly K18-positive (Figure 6e,h,k). After 60 days, most
of the cells expressed only K14 and had formed squamous
islands, but some K18-positive glandular structures were still
present and double-positive cells were also seen, particularly
in invasive zones (Figure 6f,i,l). We conclude that some of the
tumour cells have the double-positive keratin phenotype of the
ERα/BMI1 cells grown in vitro (Figure 1g), whereas others dif-
ferentiate to single-positive cells that may represent a step of
differentiation towards a luminal or myoepithelial fate, but with
a strong tendency for the latter to progress to asquamous phe-
notype. ERα is expressed and transcriptionally active in the
tumour cells, including cells that are actively proliferating.
ERα-transduced cells are genetically stable
Cells transformed with oncogenes in vitro invariably acquire
additional genetic abnormalities, either during passage in vitro
or subsequently as an adaptation to growth in vivo. Testing
with a yeast functional assay that has been used extensively to
test the p53 status of clinical samples [22] showed that p53
was wild type in the cell lines and tumours (data not shown).
To test for other abnormalities, the karyotype was examined
after 60 doublings in vitro. Cells from three different patients
transduced with the ERα, BMI1, MYC and TERT viruses had
a normal karyotype, with 46 chromosomes present in 54 out
of 55 metaphases counted (Figure 7a). To screen for smaller
genetic changes, the cells were tested on Affymetrix 50K SNP
chips (Figure 7b). MCF7 cells were used a positive control
because they contain multiple well-characterised amplicons
and deletions. Cells were tested at three different time points,
namely 6 days after removal from the patient, immediately
before injection into the mouse, and after in vitro culture of
cells recovered from established tumours. All of the samples
had a normal genotype, with no evidence of amplification,
deletion or loss of heterozygosity (Figure 7b). We conclude
that the cells transformed with ERα, BMI1, MYC and TERT
are genetically stable.
Response to anti-oestrogen therapy
To test whether the tumour cells retained their dependence on
oestrogen signalling in vitro, cells explanted from primary
tumours in mice were plated in medium containing either
oestradiol or fulvestrant (Figure 8a). The cells showed strong
inhibition of growth in fulvestrant, confirming that they remain
oestrogen-dependent for growth in vitro. To test whether the
cells were oestrogen-dependent in vivo, CFP-tagged ERα/
BMI1/MYC/TERT-transduced HMECs from three different
patients were injected into the inguinal mammary glands of
NOD/SCID mice, and tumours were allowed to develop. Three
groups of mice were tested. Two groups received an oestro-
gen pellet at the time of injection of the cells; one of these
groups also received injections of fulvestrant starting 33 days
after injection of the cells (Table 1, 'E2 + fulvestrant'). The third
group was a control group that received an empty silicon pel-
let. Tumour response was scored by fluorescence microscop-
yfor CFP 40 days after the second group began treatment with
fulvestrant (Figure 8b,c). In the group that received an
oestrogen pellet alone, only 1 of 32 grafts had minimal or
absent CFP fluorescence in the injected glands. In contrast,
18 of 22 grafts in the group that received fulvestrant displayedAvailable online http://breast-cancer-research.com/content/9/3/R38
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minimal or absent fluorescence (p < 10-8, Fisher's exact test).
In the control group that received empty pellets, fluorescent
epithelial cells were undetectable in any of the 12 injected
glands, confirming the result of the experiment shown in Figure
4a–c. We conclude that the tumour cells remain responsive to
anti-oestrogen therapy even after prolonged growth in vivo.
Metastasis of tumour cells
In 8 of 21 mice killed after 90 days there were metastases to
multiple organs, including the liver and peritoneum (Figure 9;
the HMECs were transduced with CFP). We also observed
metastases in mice from the time-course experiment (Figure 4)
as early as 30 days after injection of the cells. Metastases
were present when the volume of the primary tumour was in
Figure 5
Immunofluorescent staining of tumours harvested 35 days after injection of ERα/BMI1/TERT/MYC/CFP-transduced HMECs Immunofluorescent staining of tumours harvested 35 days after injection of ERα/BMI1/TERT/MYC/CFP-transduced HMECs. (a-i) Matched sec-
tions from one region of a tumour; (j-l) matched sections from a different region. The haematoxylin/eosin staining (H&E) in (a) shows the formation of 
tumours with dense squamous islands and diffuse infiltrating regions. The antibodies used for immunofluorescence in (b-l) are indicated in the lower 
right corner of each panel. The cyan fluorescent protein (CFP) staining in (b) and keratin 18 (K18) staining in (i) show that the tumour cells are 
derived from the injected human mammary epithelial cells (HMECs; the anti-K18 antibody is human-specific). BMI1 staining in (c) and oestrogen 
receptor alpha (ERα) staining in (d), (f) and (j) show that the HMECs retain nuclear expression of the transgenes. In (d-f), (j) and (k) it can be seen 
that some cells expressing ERα are also Ki-67-positive; (g) and (l) show expression of the ERα target gene progesterone receptor (PGR) in the 
tumour cells. There is a tendency, seen in (j) and (l), for cells with higher ERα expression to have lower PGR expression. In (h) and (i) it can be seen 
that the tumour cells are positive for keratins. The arrows in (a), (h) and (i) show a group of K18-positive glandular cells within a squamous island.Breast Cancer Research    Vol 9 No 3    Duss et al.
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the range 60 to 120 mm3. Thus, metastasis was not a late
event occurring in the presence of an enormous tumour bur-
den but an early event reflecting the intrinsic metastatic poten-
tial of the transformed cells. The histological appearance of the
metastases was identical to that of the primary tumours (Fig-
ure 9). Immunostaining of the metastases for CFP confirmed
that the metastatic cells were of human epithelial origin (Figure
9d,e). In contrast with the primary tumours, the metastases
were positive for K14 but negative for K18 (Figure 9e,j). We
conclude that transduction of normal HMECs with lentiviruses
expressing ERα, BMI1, MYC and TERT confers the ability to
form metastatic ERα-positive breast tumours.
Discussion
We have developed a model for ERα-positive breast cancer
by transformation of normal HMECs with ERα, BMI1, MYC
and TERT. Metastasis occurred in 38% of the mice after 90
days. Previous attempts to make an ERα-positive model prob-
ably failed because ERα induces growth arrest and differenti-
ation. We have not addressed the mechanism in this study, but
transforming growth factor-β is known to restrain the prolifera-
tion of ERα-positive murine mammary epithelial cells [34].
Expression of BMI1 prevents differentiation and relieves the
growth arrest, allowing the expansion of oestrogen-dependent
HMECs in culture.
There are several differences between our culture system and
those used previously. We grew the cells in floating mammos-
phere conditions before the first passage for several reasons.
At a practical level, the final step after tissue digestion is a
single-cell straining step; this facilitates efficient infection of
the cells with lentiviral vectors less than 24 hours after the
cells are removed from the patient. A second practical advan-
tage is that fibroblasts do not survive in suspension, so floating
mammosphere culture is an efficient way to eliminate fibrob-
lasts. More importantly, it is based on techniques developed
initially for propagation of neural stem cells [35] and later
adapted for culture of HMECs [8]. The mammosphere
approach enriches for bipotent progenitor cells that are capa-
ble of differentiating to myoepithelial and luminal cells, with
Figure 6
Keratin expression by tumours at different time points Keratin expression by tumours at different time points. The top panels show haematoxylin/eosin staining of tumours harvested at (a) 14 days, (b) 35 
days and (c) 60 days after injection of oestrogen receptor alpha (ERα)/BMI1/TERT/MYC/cyan fluorescent protein (CFP)-transduced human mam-
mary epithelial cells (HMECs). The lower panels show matched sections immunostained for keratins. (d-f), Keratin 14 (green); (g-i), keratin 18 (red); 
(j-l), merged image of the keratin 14 and keratin 18 signals together with a nuclear counterstain (4',6-diamidino-2-phenylindole (DAPI), blue).Available online http://breast-cancer-research.com/content/9/3/R38
Page 11 of 15
(page number not for citation purposes)
production of milk proteins by the latter after treatment with
prolactin in three-dimensional Matrigel culture [8]. The main
difference between our approach and that of Dontu and col-
leagues [8] is that we used the same medium for suspension
and adherent cell culture, and we omitted basic fibroblast
growth factor. The medium is based on B27 [15], a serum-free
medium supplement that is known to preserve the phenotype
of human tumour cells in culture better than serum-containing
media [36]. In our study, the relative importance of the medium
versus the suspension culture is unclear but we have prelimi-
nary evidence that suspension culture may not be strictly
necessary.
In the absence of a stem cell assay for HMECs it is not possi-
ble to state definitively whether mammospheres contain true
human mammary epithelial stem cells (MaSCs). It is possible
that the mammosphere approach enriches for mammary col-
ony-forming cells (Ma-CFCs) rather than mammary repopulat-
ing units (MRUs) [37,38]. The nature of the cell initially
infected with lentiviruses in our protocol is unknown because
the infections were performed on the mixed population of cells
present in reduction mammoplasty tissue. An intriguing ques-
tion is whether cells expressing the recently identified murine
MaSC markers would be more sensitive to transformation.
Given the uncertainty surrounding the identity of human
MaSCs, our main aim was to reduce the duration of growth in
vitro to limit the potential for selection of adaptations to culture
in vitro. The present study used 106 cells per fat pad injection,
for which we needed to expand the cultures in vitro for a total
of 28 days. We have preliminary results indicating that 5,000
cells are sufficient to form tumours, so it should be possible to
greatly reduce the duration of culture in vitro.
Polycomb-group genes such as BMI1,  EZH2  and  SUZ12
have repeatedly been identified as adverse prognostic factors
in breast cancer [11,12]. BMI1 is required for proliferation and
renewal of stem cells in the brain and hematopoietic system.
In mammospheres, BMI1 is thought to act as a point of con-
vergence of the Wnt, Notch and Hedgehog signals that pro-
mote stem cell renewal [10]. BMI1 probably has at least a dual
role, allowing cell proliferation by suppressing p14ARF and
p16CDKN2A expression, and preventing differentiation through
a more complex mechanism. Both processes are clearly visible
in the microarray data reported here (Figure 2). ERα-positive
tumours typically contain wild-type p53 and have fewer
genomic changes than ERα-negative tumours [39]. The ERα-
positive tumour model we have produced matches the human
disease in this respect. The most likely explanation for the
tumours to have retained wild-type p53 is that BMI1 sup-
presses p14ARF expression [9]. Previous quantitative transfor-
mation models included genes such as those encoding simian
virus 40 T antigen and p53DD to inactivate p53 [3,4]. The
MCF10A and MCF15 HMEC-derived cell lines show large dif-
ferences in their DNA damage response despite both retaining
wild-type p53 [40], and ERα-positive human breast tumours
respond poorly to chemotherapy despite having wild-type
p53. It is therefore important to note that although we have
shown that the p53 cDNA is wild type, we have not shown that
the p53 pathway is functional in our cells. The genes sup-
pressed by BMI1 in ERα-expressing cells include many
associated with neural and squamous differentiation.
Suppression of these genes presumably favours proliferation
by avoiding entry into a terminal differentiation program. We
found that BMI1 itself was one of the genes suppressed by
exogenous BMI1 expression. Bracken and colleagues showed
by chromatin immunoprecipitation (ChIP) that the Polycomb-
repressive complex 1 (PRC1) component CDX8 and the
PRC2 component SUZ12 were present at the BMI1 promoter
[27]. Suppression of PRC function by RNA-mediated interfer-
ence (RNAi) led to derepression of genes with PRC proteins
Figure 7
ERα/BMI1/TERT/MYC-transduced HMECs are genetically stable ERα/BMI1/TERT/MYC-transduced HMECs are genetically stable. (a) 
Representative karyotype of two different human mammary epithelial 
cell (HMEC) strains infected with oestrogen receptor alpha (ERα), 
BMI1, TERT and MYC viruses after continuous in vitro passage for 60 
doublings. (b) Copy number and loss of heterozygosity (LOH) plots. 
Each sample has three tracks: smoothed intensity, copy number predic-
tion by Hidden Markov Model and LOH prediction. The horizontal axis 
shows each chromosome in turn, starting with the short arm of chromo-
some 1. In the intensity track each chromosome is given a different col-
our. The first set of tracks is from MCF7 cells, which were used as a 
positive control to demonstrate that the technique can detect amplifica-
tion, deletion and LOH. The remaining three sets of tracks are, respec-
tively, cells from reduction mammoplasty tissue of patient AJ at passage 
0 (AJ P0), ERα/BMI1/TERT/MYC-transduced HMECs from the same 
patient just before they were injected into mice at passage 6 (AJ P6), 
and the same cells after recovery from established tumours (AJ 
Tumour).Breast Cancer Research    Vol 9 No 3    Duss et al.
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at the promoter [27]. On the basis of the ChIP data and the
transcriptional response to RNAi against BMI1, EED, SUZ12
and EZH2, Bracken and colleagues suggested that PcG pro-
teins autoregulate their own synthesis [27]. Autoregulation of
BMI1 itself would by definition not have been detectable in
their RNAi experiment, but when taken together with our
results it is plausible that BMI1 suppresses its own expression
through binding to its own promoter.
Wild-type ERα is not normally considered to be an oncogene,
but behaves like one in our protocol. It is well known that ERα
expression is rapidly lost from HMECs in culture. This is not
solely a consequence of growth inhibition by ERα, because
expression is still lost when cells are forced to express exoge-
nous BMI1. In comparison with previous studies, the
combination of genes we used to transform the cells seems
rather gentle. In particular, we see no need to activate Ras sig-
nalling [2-4,41]. TERT was essential for successful transfor-
mation of HMECs in previous studies [3], but BMI1 and MYC
can both activate TERT expression [42,43], so it is possible
that TERT may not be required in our protocol. We included
MYC in the protocol because BMI1 was originally identified as
an oncogene that cooperates with MYC in lymphoma produc-
tion in mice [13], MYC is commonly amplified in human breast
cancer, and several groups have reported that MYC  is
required for HMEC transformation. Indeed, when Elenbaas
and colleagues [3] used an HMEC transformation protocol
lacking MYC, the cells spontaneously amplified MYC during
culture in vitro. We used a wild-type MYC (c-myc) clone for
our studies, rather than the activated form of MYC (T58A)
used by Kendall and colleagues [4]. Despite the strong evi-
dence that MYC  is important, the requirements may differ
when the selection conditions are changed, and we have pre-
liminary evidence that MYC may not be required in ERα/BMI/
TERT-transduced HMECs, at least for the initial stages of
tumour formation.
It is intriguing that the transformed HMECs in our model can
form polarised epithelial structures in vivo that express the cor-
rect luminal and basal keratins (Figure 6). This indicates that
the double-positive keratin staining pattern in vitro is more
likely to reflect a specific progenitor state than a loss of control
of lineage-specific gene expression. Unlike the primary
tumours in the mammary gland, the metastases were K18-
negative. This suggests that the cells differentiate in response
to signals from their local environment and that the mammary
fat pad supplies specific signals that promote luminal keratin
expression. Although the tumours contained regions of inva-
sive adenocarcinoma, the predominant pathology was squa-
mous carcinoma. Squamous differentiation is uncommon in
human breast tumours. The squamous differentiation we
observed in the NOD/SCID mice may reflect a general prop-
erty of the mouse mammary fat pad model, a specific property
of the target cell of the in vitro transformation protocol, or a
defect in the transactivation of critical ERα target genes in the
transformed cells. In comparison with the human breast, the
mouse mammary gland contains much less fibrous connective
tissue [44]. To promote engraftment of HMECs in the mouse
mammary gland, human fibroblasts are commonly injected
either at the same time as the HMECs or a few days earlier, to
'humanise' the stroma [32]. Human cancer-associated fibrob-
lasts (CAFs) are similarly used to promote engraftment of
human tumour cells in mice [45]. It is possible that the HMFs
we injected together with the HMECs may have contributed to
Figure 8
Response to anti-oestrogen therapy Response to anti-oestrogen therapy. (a) Tumour cells were recovered from a mouse, then grown in the presence of oestradiol (E) or fulvestrant (F). 
(b,c) Mammary glands of mice that received an oestrogen pellet before injection of the tumour cells, followed by either no additional treatment (b) or 
weekly subcutaneous injections of fulvestrant to block oestrogen signalling (c). Upper panels, normal light; lower panels, cyan fluorescent protein 
(CFP) fluorescence. Only the human mammary epithelial cells were infected with the CFP-expressing virus in this experiment.Available online http://breast-cancer-research.com/content/9/3/R38
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the squamous phenotype, but injection of our HMECs without
HMFs led to the formation of tumours with similar kinetics and
histology (data not shown). As mentioned above, we do not
know the identity of the target cell of the transformation proto-
col. The mammosphere protocol enriches for mammary epi-
thelial progenitor cells, but it is possible that expression of
BMI1 promotes the survival of more differentiated cells or,
conversely, forces progenitors to adopt a more stem-cell-like
phenotype. HMEC protocols commonly give rise to squamous
tumours in mice [3,46,47], so we consider it unlikely that the
mammosphere protocol has led to the expansion of cells that
are unrelated to mammary epithelium. Another possibility is
that, despite expressing ERα, the cells are unable to respond
appropriately to it. The gene expression profile of breast
tumours is dominated by genes that are tightly associated with
ERα status [48]. Many of these genes are direct targets of
ERα but others are thought to represent markers of cell type.
Some classic ERα target genes, such as the progesterone
and prolactin receptor genes, were induced by oestradiol in
the ERα/BMI1 HMECs, but others, such as TFF1 and XBP1,
were not (Figure 2; the full data set is available in the GEO
database under accession number GSE6548). The unin-
duced group includes many of the genes shown by RNA inter-
ference to require co-activation by FOXA1 [49]. Because
FOXA1 is expressed only weakly in the transformed cells,
transduction with a FOXA1 vector might lead to the activation
of a broader range of ERα target genes and suppression of the
squamous phenotype. More generally, there may be regulators
of the differentiation programme of mammary epithelial cells,
such as GATA3 or TP73L, that are not correctly expressed in
the xenografts. We are currently testing these models to
develop a transformation protocol that more faithfully repro-
duces the histology of human breast tumours.
It has long been known that ERα-positive breast tumours
metastasise early, leading to distant relapse many years after
excision of the primary tumour. In comparison with ERα-nega-
tive tumours, they have a better initial prognosis but this is
followed by a relentless increase in breast cancer-specific
mortality that continues even 15 years after treatment of the
primary tumour [50]. It is tempting to speculate that the correct
paradigm for these tumours is a low-grade lymphoma: a sys-
temic disease characterised by few genetic changes and poor
response to therapy. Intriguingly, there is a class of ERα-posi-
tive breast tumours that have only a single change on genomic
profiling: an unbalanced translocation leading to gain of chro-
mosome 1q and loss of chromosome 16q [51]. For this model
to be correct, metastasis would have to occur early. Metasta-
sis has not previously been reported in studies with HMECs
transformed with defined oncogenes [3]. At early time points
the transformed HMECs reported here invaded the fat pad
rapidly, forming a prominent duct-like structure that arose
either from cells deposited in the needle track or by the migra-
tion of cells out from the main mass (Figure 4g–i). We have not
tested the invasive properties of the cells in vitro, but the spe-
Figure 9
Metastasis formation after injection of transformed cells into the mam- mary gland Metastasis formation after injection of transformed cells into the mam-
mary gland. Metastases were observed from 30 to 90 days after injec-
tion of oestrogen receptor alpha (ERα)/BMI1/TERT/MYC-transformed 
human mammary epithelial cells (HMECs). (a-e) Peritoneal metastases 
90 days after injection. (f-j) liver metastases 30 days after injection. 
(a,f) normal light, (b,g) cyan fluorescent protein (CFP) fluorescence, 
(c,h) haematoxylin/eosin staining, (d,i) CFP immunostain (green) with 
4',6-diamidino-2-phenylindole (DAPI) counterstain (blue), (e,j) keratin 
14 immunostain (green) with DAPI counterstain (blue). (c-e,h-j) 
Matched tissue sections of peritoneal and liver metastases, respec-
tively. Liver tissue is stained yellow in (i) and (j) by non-specific binding 
of secondary antibodies coupled to Alexa 488 and Alexa 568. Only the 
HMECs were infected with the CFP-expressing virus in this experiment.Breast Cancer Research    Vol 9 No 3    Duss et al.
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cific combination of genes used to transform the cells certainly
triggers an invasive and metastatic program in vivo. Because
the key difference between this model and previous HMEC
models is ERα expression, it is tempting to speculate that ERα
itself has a critical role in the early metastasis of ERα-positive
human breast tumours.
Conclusion
We have created a new model for ERα-positive breast cancer
by transduction of normal HMECs with lentiviruses expressing
ERα, BMI1, MYC and TERT. The transformed cells are oestro-
gen-dependent for growth, wild-type for p53, diploid, and
genetically normal as judged by hybridisation of tumour-cell
DNA to SNP chips. The lack of secondary genetic changes
and the high efficiency of tumour formation suggest that the
cells are quantitatively transformed by the transgenes. The
cells form disseminated peritoneal and liver metastases, a fea-
ture not previously seen with genetically defined, ERα-nega-
tive breast cancer models.
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